# Regeneron (REGN) — Overview

REGN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/regn

## Price

Last close $789.09 on Oct 16, 2026. 52-week range $569.17 – $852.03.

## Company profile

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

## Financials

| Metric | Value |
| --- | --- |
| Revenue (trailing twelve months) | $15.5B |
| Revenue (quarter) | $4.3B |
| Revenue growth (year over year) | 16.73% |
| Gross profit (trailing twelve months) | $13.2B |
| Gross margin | 84.86% |
| Net income (trailing twelve months) | $4.3B |
| Net income (quarter) | $1.3B |
| Net income growth (year over year) | -6.81% |
| Net margin | 27.86% |
| Return on equity | 14.04% |
| EPS (trailing twelve months) | $41.87 |
| Book value per share | $306.69 |
| P/E (trailing twelve months) | 18.8 |
| Price to book | 2.6 |
| Debt to assets | 24.01% |
| Payout ratio | 8.37% |
| Dividend yield | 0.48% |

## Frequently Asked Questions

### Is Regeneron (REGN) profitable?

Yes. Regeneron earned $4.3B in net income over the trailing twelve months, a net margin of 27.86%.

### How much revenue does Regeneron (REGN) make?

Regeneron generated $15.5B in revenue over the trailing twelve months, up 16.73% year over year.

### What is REGN's P/E ratio?

Regeneron trades at 18.8 times trailing twelve-month earnings, on an EPS of $41.87.

### How do I buy stock in Regeneron (REGN)?

REGN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at [Light Horse Dashboard](https://portal.lighthorse.io), the trading API, or an [AI agent connected over MCP](/instructions/ai/claude). The trade panel on this page places the order once you are signed in.

## Similar Stocks

- [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock
- [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock
- [LLY](https://www.lighthorse.io/tickers/lly) — Eli Lilly and Company Common Stock
- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock
- [AMGN](https://www.lighthorse.io/tickers/amgn) — Amgen Inc. - Common Stock
- [NTLA](https://www.lighthorse.io/tickers/ntla) — Intellia Therapeutics, Inc. - Common Stock
- [GILD](https://www.lighthorse.io/tickers/gild) — Gilead Sciences, Inc. - Common Stock
- [MRK](https://www.lighthorse.io/tickers/mrk) — Merck & Company, Inc. Common Stock (new)
- [VIR](https://www.lighthorse.io/tickers/vir) — Vir Biotechnology, Inc. - Common Stock
- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock

---

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).